av Janncike Kristoffersen | aug 5, 2020
Business opportunity Scientists at Oslo University Hospital have developed a potent and specific inhibitor of tankyrase (OM-153), a master regulator of both WNT and YAP signaling pathways. These pathways are involved in the establishment and maintenance of cancer; at...
av Kim Larsen | jun 29, 2020
Business opportunity Inventors at the University of Oslo/Oslo University Hospital have developed an engineered human albumin variant with extended in vivo half-life. This unique albumin can be used as a fusion partner to improve the pharmacokinetics of...
av Kim Larsen | jun 29, 2020
Business opportunity Inventors at the University of Oslo/Oslo University hospital have developed a unique and versatile antibody Fc technology platform (“REW”). The technology increases the serum half-life and biodistribution properties of IgG antibodies and Fc...
av Kim Larsen | jun 29, 2020
Business opportunity Technical debt in software development consists of sub-optimal design solutions that are beneficial in the short term, but create costly negative impact in the long run, e.g. costly maintenance changes and impossibility to evolve the system....
